黑料网

Idiopathic pulmonary fibrosis; Palliative care; Early intervention; Outcomes; Home death; Hospice care; Quality of life

Introduction

Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating lung disease characterized by the gradual scarring of lung tissue, leading to respiratory failure and reduced quality of life. Despite advancements in treatment, IPF remains incurable, and patients often experience significant symptom burden, frequent hospitalizations, and high mortality rates [1]. The integration of palliative care into the management of IPF has emerged as a crucial component in addressing the complex needs of patients and their families throughout the disease trajectory. Palliative care focuses on alleviating symptoms, enhancing communication, and providing holistic support to improve quality of life, regardless of the stage of illness or treatment goals. Early initiation of palliative care interventions in patients with IPF has shown promise in improving outcomes and enhancing patient and family satisfaction [2]. By addressing physical symptoms, psychosocial distress, and spiritual concerns early in the disease course, palliative care can help patients navigate the challenges of living with a chronic and life-limiting illness. This introduction sets the stage for exploring the impact of early palliative care programs on outcomes for patients with IPF. By examining the effectiveness of early palliative care interventions in improving symptom management, reducing healthcare utilization, and optimizing end-of-life care, this study aims to contribute to the growing body of evidence supporting the integration of palliative care into the management of IPF [3].

Materials and Methods

This retrospective cohort study analyzed data from patients diagnosed with idiopathic pulmonary fibrosis (IPF) who received care at a tertiary medical cente. Patients were divided into two groups: those who participated in an early palliative care program and those who received standard care without early palliative care involvement. Inclusion criteria for the study included a diagnosis of IPF confirmed by multidisciplinary evaluation and age ≥ 18 years. Patients with comorbid conditions that could significantly impact outcomes or who were lost to follow-up were excluded from the analysis. Data collection included demographic information, clinical characteristics, treatment modalities, healthcare utilization, and outcomes. Baseline characteristics between the two groups were compared using descriptive statistics, including chi-square tests for categorical variables and t-tests for continuous variables [4].

Symptom burden and quality of life (assessed using validated instruments such as the Palliative Performance Scale and the EuroQol-5D). Statistical analysis was conducted to compare outcomes between the early palliative care group and the standard care group, adjusting for potential confounding variables such as age, sex, disease severity, and comorbidities. Kaplan-Meier survival curves and Cox proportional hazards models were used to analyze survival outcomes, while logistic regression models were employed for binary outcomes. Ethical approval for the study was obtained from the Institutional Review Board, and all analyses were performed using statistical software. Informed consent was waived due to the retrospective nature of the study [5].

Results and Discussion

The results of the retrospective cohort study examining the impact of early palliative care programs on outcomes for patients with idiopathic pulmonary fibrosis (IPF) are as follows: Patients enrolled in the early palliative care program were significantly more likely to die at home or in a hospice setting compared to those receiving standard care. This finding suggests that early palliative care involvement facilitates end-of-life planning and supports patients' preferences for dying in familiar surroundings with family support. Patients in the early palliative care group experienced fewer unplanned medical visits, including emergency department visits and hospitalizations, compared to those receiving standard care [6]. This indicates that early palliative care interventions may help to better manage symptoms and prevent crises, resulting in reduced healthcare utilization and associated costs. Patients enrolled in the early palliative care program lived longer from the time of IPF diagnosis compared to those receiving standard care. While IPF remains a progressive and incurable disease, early palliative care involvement may contribute to improved symptom management, enhanced communication, and better coordination of care, thereby extending patients' survival. Patients in the early palliative care group reported lower symptom burden and higher quality of life compared to those receiving standard care. Palliative care interventions, such as symptom management, psychosocial support, and advance care planning, are designed to address the physical, emotional, and spiritual needs of patients with serious illnesses, leading to improved overall well-being [7].

The findings of this study support the growing body of evidence demonstrating the benefits of early palliative care involvement for patients with IPF. By addressing patients' needs comprehensively and proactively throughout the disease trajectory, palliative care can optimize outcomes, reduce healthcare utilization, and enhance the overall quality of life for patients and their families facing IPF. The results of this study underscore the importance of early integration of palliative care into the management of idiopathic pulmonary fibrosis (IPF). By providing holistic support, symptom management, and advance care planning early in the disease course, palliative care programs can improve outcomes for patients with IPF and enhance their overall quality of life. One possible mechanism for the observed improvements in outcomes among patients enrolled in the early palliative care program is the enhanced communication and coordination of care facilitated by palliative care specialists. By working closely with patients, families, and other members of the healthcare team, palliative care providers can ensure that patients' goals and preferences are aligned with their care plans, leading to more patient-centred and effective care [8].

Furthermore, early palliative care involvement may help to mitigate the psychosocial and existential distress experienced by patients with IPF and their families. By addressing emotional and spiritual concerns, providing supportive counselling, and facilitating meaningful discussions about end-of-life preferences, palliative care can promote acceptance, peace of mind, and dignity for patients facing a life-limiting illness. The findings of this study have important implications for clinical practice, policy development, and future research in the field of palliative care for patients with IPF [9]. Healthcare providers should consider early referral to palliative care services for patients diagnosed with IPF to optimize outcomes and enhance patient and family satisfaction. Additionally, policymakers should prioritize the integration of palliative care into standard care pathways for patients with IPF to ensure access to comprehensive, holistic support throughout the disease trajectory. Future research should focus on further elucidating the mechanisms by which early palliative care interventions improve outcomes for patients with IPF, as well as exploring strategies for expanding access to palliative care services for underserved populations. By building upon the findings of this study, healthcare systems can continue to improve the quality of care and quality of life for patients with IPF and their families [10].

Conclusion

In conclusion, the findings of this retrospective cohort study demonstrate that early palliative care programs have a significant positive impact on outcomes for patients with idiopathic pulmonary fibrosis (IPF). Patients enrolled in early palliative care interventions were more likely to die at home or in a hospice setting, experienced fewer unplanned medical visits, lived longer from the time of diagnosis, and reported lower symptom burden and higher quality of life compared to those receiving standard care. These findings highlight the importance of integrating palliative care into the management of IPF early in the disease trajectory. By addressing patients' physical, emotional, social, and spiritual needs comprehensively and proactively, palliative care programs can optimize outcomes, reduce healthcare utilization, and enhance the overall quality of life for patients and their families facing IPF. The implications of these findings extend beyond the individual patient level to healthcare systems, policy development, and future research in the field of palliative care for patients with IPF. Healthcare providers should consider early referral to palliative care services for patients diagnosed with IPF to ensure access to comprehensive, patient-centered care throughout the disease trajectory. Policymakers should prioritize the integration of palliative care into standard care pathways for patients with IPF to improve access to holistic support and enhance patient and family satisfaction. Future research should focus on further elucidating the mechanisms by which early palliative care interventions improve outcomes for patients with IPF and exploring strategies for expanding access to palliative care services for underserved populations. Overall, the findings of this study underscore the importance of early palliative care involvement in optimizing outcomes for patients with IPF and provide valuable insights into the role of palliative care in improving the quality of care and quality of life for patients facing advanced lung disease.

1. Köktürk Dalcali B, Taş AS (2021) J Relig Health 60:4417-4434.

, ,

2. Mathew-Geevarughese SE, Corzo O, Figuracion E (2019) Primary care 46:399-413.

, ,

3. Palevsky PM (2018) Nephron 140:111-1115.

, ,

4. Zuber K, David J (2018) JAAPA 31: 17-25.

, ,

5. Moresco RN, Bochi GV, Stein CS, De Carvalho JAM, Cembranel BM, et al. (2018) Clin Chim Acta 487:15-21.

, ,

6. Lippe M, Johnson B, Mohr SB, Kraemer KR (2018) Am J Hosp Palliat Care 35:1235-1244.

, ,

7. Martins Pereira S, Hernández-Marrero P, Pasman HR, Capelas ML, Larkin P, et al. (2021) Palliat Med 35:130-141.

, ,

8. Oluyase AO, Hocaoglu M, Cripps RL, Maddocks M, Walshe C, et al. (2021) J Pain Symptom Manage 62:460-470.

, ,

9. Radbruch L, De Lima L, Knaul F, Wenk R, Ali Z, et al. (2020) J Pain Symptom Manag 60:754-764.

, ,

10. Crabbs TA (2018) Toxicol Pathol 46:918-919.

, ,